Save the Date

Who: Wiskott-Aldrich Foundation
What: Externally-Led Patient Focused Drug Development (EL-PFDD) meeting on Severe WAS (Classic WAS) and Mild WAS (X-Linked Thrombocytopenia, or XLT)
When: August 19, 2022. 10 a.m. - 3 p.m. EDT
Where: Virtual
Why: See below

What is an externally-led patient-focused drug development meeting?

Externally-led Patient Focused Drug (EL-PFDD) meetings give the Food and Drug Administration (FDA) and other key stakeholders — including medical product developers, health care providers, and federal partners — an important opportunity to hear directly from patients, their families, caregivers, and patient advocates about the symptoms that matter most to them, the impact the disease has on patients’ daily lives, and patients’ experiences with currently available treatments. This input can inform FDA’s decisions and oversight both during drug development and during their review of a marketing application for a new drug.

Learn more about externally-led Patient-Focused Drug Development meetings.

You must be logged in to add gadgets that are only visible to you